Medications & treatment options

Peptides, NAD+ & Longevity Compounds: Evidence vs. Hype

Peptides sit in a gray zone between approved drugs, compounded products, and research chemicals, and the marketing usually runs far ahead of the human data. This cluster collects the peptide and longevity-compound reviews — each one separating FDA-approved uses from animal studies and anecdote, and noting the legal and sourcing status.

65 research articles · newest update October 2026

Recently updated

Does NAD+ Slow Aging? What Human Trials of NMN and NR Actually Show

NAD+ boosters like NMN and nicotinamide riboside raise NAD+ levels, but do they slow aging? Across human trials, effects on muscle, cognition, blood pressure and metabolism were mostly null, with a few small exceptions, and a 2026 review found no outcome trials of IV NAD+ drips.

9 min read · Updated October 2026

5-Amino-1MQ for Weight Loss: What the Evidence Actually Shows

5-Amino-1MQ is an oral NNMT-inhibitor sold as a fat-loss 'peptide.' It reduced fat mass in obese mice, but there is no human trial of any kind and no FDA approval. We verified the evidence live in PubMed.

7 min read · Updated August 2026

Adipotide for Fat Loss: Dramatic in Monkeys, Never Proven in Humans

Adipotide caused dramatic weight loss in obese primates by destroying white fat's blood supply — but also triggered kidney toxicity, and no completed human obesity trial exists.

9 min read · Updated August 2026

AOD-9604 for Weight Loss: The Obesity Drug That Failed in Human Trials

AOD-9604 was built specifically as an anti-obesity drug and reached human Phase 2 trials — but it failed to produce meaningful weight loss and was abandoned. We review the positive animal data, the negative human result, the regulatory reality, and how it compares to FDA-approved obesity drugs.

9 min read · Updated August 2026

All 65 articles in this topic

Most recently updated first.